[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Analyzing...

07/17/2025 - 04:01 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Telomir Pharms

NASDAQ:TELO

TELO Rankings

#6335 Ranked by Market Cap

N/A Ranked by Dividends

#42 Top Loser

TELO Latest News

Jul 18, 2025

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Jun 18, 2025

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Jun 11, 2025

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Jun 5, 2025

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Jun 2, 2025

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

TELO Stock Data

Market Cap 34.82M

Float 19.59M

Insiders Ownership 34.17%

Institutions Ownership 12.07%

Short Percent 6.29%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City MIAMI